Posted by Michael Wonder on 25 Aug 2022
Tagrisso approved in Japan for the adjuvant treatment of patients with early-stage EGFR mutated lung cancer
25 August 2022 - Approval based on results from the ADAURA Phase 3 trial.
AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor mutated non-small-cell lung cancer after surgery.
